Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Paylocity (PCTY) - Cheap Enough for a Tactical Rebound Trade
Strong unit economics, low leverage and a depressed share price create an asymmetric swing opportunity
Paylocity’s latest quarter showed solid revenue and margin durability, a lightweight debt profile and a large marketplace of midmarket customers. Th...
Upgrading LATAM (LTM) to Strong Buy - A Tactical Long with Clear Entry, Stops and Targets
Post-pandemic demand, fleet refresh and resumed capital returns give LATAM a shot at re-rating — trade plan included.
I am upgrading LATAM Airlines (LTM) to Strong Buy. The stock is trading near $62.6 after a volatile run from the low $20s-30s, while the company repor...
Palantir: AIP Adoption Is Finally Converting Into Profits — Tactical Long
Earnings beat and accelerating commercial uptake make PLTR a buy for the next 3–12 months; actionable entry, stop, and targets included.
Palantir's Q3 2025 results and 02/02/2026 earnings print point to accelerating adoption of its AI products. Revenue and cash flow are scaling while ma...
Patria (PAX) - Emerging-market M&A and Fee Momentum Create a Tactical Long Opportunity
Earnings beat, strategic acquisitions and a steady dividend make a 6-12 month long trade attractive; manage with a tight stop and clear targets.
Patria reported a modest Q4 beat on 02/03/2026 and has executed several acquisitions to expand credit and U.S. lower-middle-market capabilities. With ...
WPP: Deep Value Entry on an Advertising Giant—Dividend Yield Flags Distress, But Upside Exists
Price collapse + heavy dividend implies cash return >10% at current levels; trade idea with defined entry, stop and targets.
WPP plc (WPP) has fallen from recent highs into the teens. The company's declared dividend payments in 2025 imply a cash yield north of 11% at the cur...
Genworth Financial: Buy the Balance-Sheet, Position for a Sizable Re-rating
GNW trades well below book value. This is a tactical long for patient investors betting on a sum-of-the-parts rerating and execution on LTC and capital actions.
Genworth (GNW) is a classic insurance deep-value opportunity: tangible equity of roughly $8.8B (attributable to parent) against a market cap near ~$3....
CrowdStrike After the Pullback: Buy the Growth, Not the Multiple
Correction opened a tactical long - same Falcon-led story, bigger margin for error
CrowdStrike (CRWD) has corrected roughly 25-30% from its 2025 highs while its revenue trajectory, cash generation and platform positioning remain inta...
Cenovus: Buy the Integration, Not Just the Deal - MEG Execution Will Drive Outperformance
The MEG Energy close is priced in; converting reserves to reliable free cash flow is the next leg for CVE.
Cenovus (CVE) recently closed the MEG Energy acquisition (11/13/2025). The trade is a tactical long: buy the stock on near-term weakness with a tight ...
Medpace: Quarterly Beat but Valuation Looks Priced for Perfection – Short/Sell Into Strength Trade
Q4 beat and strong cash generation; stagnant backlog commentary and a rich multiple make a tactical short or sell-on-strength opportunity.
Medpace reported another solid quarter (Q4/FY2025) with revenue and EPS beats and strong operating cash flow, but the market reacted negatively. The c...
PTEN: Buy the Cash-Flow Story, Skip the Data-Center Noise
Patterson-UTI prefers steady cash returns and balance-sheet repair over speculative expansion - a disciplined, dividend-backed trade idea.
Patterson-UTI (PTEN) is generating consistent operating cash flow even as GAAP earnings wobble. Management looks to return cash (dividend raised to $0...
Hims & Hers: Buy the Dip — Don’t Be Driven by the Headlines
A tactical long for traders who view regulatory noise as overreaction, with clear entry, stop and targets.
Shares plunged after headlines about a Novo Nordisk lawsuit and an FDA crackdown on compounding GLP-1s. That created a tradable dislocation: Hims & He...
Solid Biosciences - Positive FDA Interaction on SGT-003 Frames a Tactical Long with Defined Risk/Reward
SGT-003's favorable FDA meeting (assumed) clears path to near-term milestones; company balance sheet gives runway — trade idea with entry, stop and targets.
Solid Biosciences (SLDB) looks set for a catalyst-driven re-rate if the FDA interaction on SGT-003 is indeed constructive. The company reported $236.1...